Form 8-K - Current report:
SEC Accession No. 0001104659-22-125884
Filing Date
2022-12-09
Accepted
2022-12-09 16:30:29
Documents
12
Period of Report
2022-12-05
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2232346d1_8k.htm   iXBRL 8-K 27171
  Complete submission text file 0001104659-22-125884.txt   200048

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA kala-20221205.xsd EX-101.SCH 3027
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE kala-20221205_lab.xml EX-101.LAB 34476
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kala-20221205_pre.xml EX-101.PRE 22591
6 EXTRACTED XBRL INSTANCE DOCUMENT tm2232346d1_8k_htm.xml XML 3608
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
Kala Pharmaceuticals, Inc. (Filer) CIK: 0001479419 (see all company filings)

EIN.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 221455175
SIC: 2834 Pharmaceutical Preparations